Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference
07:30am, Wednesday, 03'rd Nov 2021
JENA, GERMANY, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announ
InflaRx Secures €44M Grant From German Govt To Advance Its COVID-19 Trial
03:42pm, Tuesday, 19'th Oct 2021
The German Ministry of Education & Research and the Ministry of Health have granted €43.7 million to InflaRx N.V. (NASDAQ: IFRX) to support the development of vilobelimab for COVID-19 patients.
JENA, Germany, Oct. 19, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, a
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
07:30am, Tuesday, 12'th Oct 2021
JENA, Germany, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, a
InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07:30am, Thursday, 09'th Sep 2021
JENA, Germany, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, annou
IFRX Stock: Over 9% Increase Pre-Market Explanation
09:11am, Wednesday, 08'th Sep 2021
The stock price of Inflarx NV (NASDAQ: IFRX) increased by over 9% pre-market. This is why it happened.
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint
07:30am, Wednesday, 08'th Sep 2021
JENA, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,
InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks
01:54pm, Wednesday, 25'th Aug 2021
Most are asking is an investment in InflaRx worth it? Presumably, this question is in response to the FDA regulatory hurdle currently playing out with the NDA for avacopan by ChemoCentryx.
JENA, Germany, Aug. 10, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, a
InflaRx to Present at the BTIG Virtual Biotechnology Conference
07:30am, Friday, 06'th Aug 2021
JENA, Germany, Aug. 06, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will p
InflaRx to Present at the Raymond James Human Health Innovation Conference
07:30am, Thursday, 17'th Jun 2021
JENA, Germany, June 17, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, w
A Trio of Net Current Asset Value Stock Picks
12:07pm, Wednesday, 09'th Jun 2021
There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the
InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab
07:30am, Tuesday, 08'th Jun 2021
JENA, Germany, June 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, t
Tony Gibney Joins InflaRx Board of Directors
07:30am, Friday, 21'st May 2021
JENA, Germany, May 21, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, to
InflaRx Reports First Quarter 2021 Financial & Operating Results
07:30am, Wednesday, 12'th May 2021
JENA, Germany, May 12, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announc
